<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542307</url>
  </required_header>
  <id_info>
    <org_study_id>2009P000380</org_study_id>
    <secondary_id>2009P000380</secondary_id>
    <nct_id>NCT01542307</nct_id>
  </id_info>
  <brief_title>Normobaric Oxygen (NBO) Therapy in Acute Migraine</brief_title>
  <official_title>Normobaric Oxygen (NBO) Therapy in Acute Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study investigating the therapeutic potential of breathing 100% oxygen in
      acute migraine headache.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 40 adult subjects will be enrolled, male and female. Subjects will be consented to
      inhale either Normobaric Oxygen (NBO) or Room air for 30 minutes at the start of their
      migraine attacks. Outcomes will be assessed during and after gas treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Scores From 0-30 Minutes on a Visual Analog Scale (VAS)</measure>
    <time_frame>From baseline (0 minutes) to 30 mins</time_frame>
    <description>The mean change in VAS pain scores from 0 minutes to 30 minutes was selected as the primary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Score From 0-15 Minutes on the Visual Analogue Scale (VAS)</measure>
    <time_frame>Baseline (0 minutes) to 15 minutes</time_frame>
    <description>The mean change in VAS pain scores from 0 minutes to 15 minutes was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pain Score From 0-60 Minutes on the Visual Analogue Scale (VAS)</measure>
    <time_frame>Baseline (0 minutes) to 60 minutes</time_frame>
    <description>The mean change in VAS pain scores from 0 minutes to 60 minutes was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Pain Severity Score 0-1 on the Visual Analogue Scale (VAS)</measure>
    <time_frame>60 minutes</time_frame>
    <description>The percentage of migraine attacks with the final (60 minute) VAS pain score 0-1 was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Pain Score 0-1 or Score Improved 3 or More Points on the Visual Analogue Scale (VAS)</measure>
    <time_frame>60 minutes</time_frame>
    <description>The percentage of migraine attacks with the final (60 minute) VAS pain score either 0-1, or a 3-point improvement from baseline, was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Visual Symptom Score 0-1 on the Visual Analog Scale (VAS)</measure>
    <time_frame>60 minutes</time_frame>
    <description>The percentage of migraine attacks with the final (60 minute) VAS visual symptom score 0-1 was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final Nausea Score 0-1 on the Visual Analog Scale (VAS)</measure>
    <time_frame>60 minutes</time_frame>
    <description>The percentage of migraine attacks with the final (60 minute) VAS nausea score 0-1 was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Post-gas Therapy Medication Use</measure>
    <time_frame>60 minutes</time_frame>
    <description>The percentage of migraine attacks requiring the use of one or more anti-migraine medications after the period of gas inhalation, was selected as a secondary outcome measure.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen is inhaled for 30 minutes during migraine attack</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Room Air</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Medical air inhaled for 30 minutes during migraine attack</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>Oxygen is inhaled for 30 minutes during migraine attack</description>
    <arm_group_label>Oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Room air</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Room Air</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects with frequent migraine (at least 1 attack per month)

        Exclusion Criteria:

          -  Secondary (non-migraine) headache

          -  Chronic obstructive pulmonary disease

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aneesh B Singhal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Singhal AB, Maas MB, Goldstein JN, Mills BB, Chen DW, Ayata C, Kacmarek RM, Topcuoglu MA. High-flow oxygen therapy for treatment of acute migraine: A randomized crossover trial. Cephalalgia. 2017 Jul;37(8):730-736. doi: 10.1177/0333102416651453. Epub 2016 May 20.</citation>
    <PMID>27206964</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <results_first_submitted>October 16, 2016</results_first_submitted>
  <results_first_submitted_qc>February 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2017</results_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Aneesh B. Singhal, MD</investigator_full_name>
    <investigator_title>Associate Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>oxygen therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>22 subjects enrolled</recruitment_details>
      <pre_assignment_details>22 subjects enrolled - each subject generated data for one or more migraine attacks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oxygen-treated Migraine Attacks</title>
          <description>Oxygen is inhaled for 30 minutes during a migraine attack</description>
        </group>
        <group group_id="P2">
          <title>Medical Air-treated Migraine Attacks</title>
          <description>Medical air is inhaled for 30 minutes during a migraine attack</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22">Each subject inhaled Oxygen for 30 minutes in blinded fashion for 2 of the 4 migraine attacks</participants>
                <participants group_id="P2" count="22">Each subject inhaled Medical Air for 30 minutes in blinded fashion for 2 of the 4 migraine attacks</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Enrolled Subjects</title>
          <description>Oxygen or Medical Air is inhaled in random order for 30 minutes during each migraine attack (total 4 attacks)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Migraine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Migraine w Aura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine without Aura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Employed Full Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Employed Full Time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education Level</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>College or higher</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>School or lower</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Single</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Prior smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of migraine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vascular risk factors (eg. hypertension)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>One or more lifetime ED visits</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>One or more ED visits in prior year</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Visited</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not visited</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triptans for acute migraine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NSAIDs/acetaminophen for acute migraine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Opioids for acute migraine</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-seizure meds for migraine prevention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Beta-blockers for migraine prevention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Using botulinum toxin for migraine prevention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Using</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Scores From 0-30 Minutes on a Visual Analog Scale (VAS)</title>
        <description>The mean change in VAS pain scores from 0 minutes to 30 minutes was selected as the primary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
        <time_frame>From baseline (0 minutes) to 30 mins</time_frame>
        <population>Number of migraine attacks treated with Oxygen or Medical Air</population>
        <group_list>
          <group group_id="O1">
            <title>Oxygen</title>
            <description>Oxygen is inhaled for 30 minutes during migraine attack
Oxygen: Oxygen is inhaled for 30 minutes during migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Room Air</title>
            <description>Medical air inhaled for 30 minutes during migraine attack
Room air: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Scores From 0-30 Minutes on a Visual Analog Scale (VAS)</title>
          <description>The mean change in VAS pain scores from 0 minutes to 30 minutes was selected as the primary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
          <population>Number of migraine attacks treated with Oxygen or Medical Air</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Migraine attacks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Migraine attacks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="1.42"/>
                    <measurement group_id="O2" value="1.22" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.674</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Score From 0-15 Minutes on the Visual Analogue Scale (VAS)</title>
        <description>The mean change in VAS pain scores from 0 minutes to 15 minutes was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
        <time_frame>Baseline (0 minutes) to 15 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxygen</title>
            <description>Oxygen is inhaled for 30 minutes during migraine attack
Oxygen: Oxygen is inhaled for 30 minutes during migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Room Air</title>
            <description>Medical air inhaled for 30 minutes during migraine attack
Room air: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Score From 0-15 Minutes on the Visual Analogue Scale (VAS)</title>
          <description>The mean change in VAS pain scores from 0 minutes to 15 minutes was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Migraine attacks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Migraine attacks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="1.09"/>
                    <measurement group_id="O2" value="0.44" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pain Score From 0-60 Minutes on the Visual Analogue Scale (VAS)</title>
        <description>The mean change in VAS pain scores from 0 minutes to 60 minutes was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
        <time_frame>Baseline (0 minutes) to 60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxygen</title>
            <description>Oxygen is inhaled for 30 minutes during migraine attack
Oxygen: Oxygen is inhaled for 30 minutes during migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Room Air</title>
            <description>Medical air inhaled for 30 minutes during migraine attack
Room air: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Score From 0-60 Minutes on the Visual Analogue Scale (VAS)</title>
          <description>The mean change in VAS pain scores from 0 minutes to 60 minutes was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Migraine attacks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Migraine attacks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="2.23"/>
                    <measurement group_id="O2" value="1.57" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Pain Severity Score 0–1 on the Visual Analogue Scale (VAS)</title>
        <description>The percentage of migraine attacks with the final (60 minute) VAS pain score 0-1 was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxygen</title>
            <description>Oxygen is inhaled for 30 minutes during migraine attack
Oxygen: Oxygen is inhaled for 30 minutes during migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Room Air</title>
            <description>Medical air inhaled for 30 minutes during migraine attack
Room air: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Final Pain Severity Score 0–1 on the Visual Analogue Scale (VAS)</title>
          <description>The percentage of migraine attacks with the final (60 minute) VAS pain score 0-1 was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
          <units>percentage of attacks</units>
          <param>Number</param>
          <units_analyzed>Migraine attacks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Migraine attacks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Pain Score 0-1 or Score Improved 3 or More Points on the Visual Analogue Scale (VAS)</title>
        <description>The percentage of migraine attacks with the final (60 minute) VAS pain score either 0-1, or a 3-point improvement from baseline, was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxygen</title>
            <description>Oxygen is inhaled for 30 minutes during migraine attack
Oxygen: Oxygen is inhaled for 30 minutes during migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Room Air</title>
            <description>Medical air inhaled for 30 minutes during migraine attack
Room air: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Final Pain Score 0-1 or Score Improved 3 or More Points on the Visual Analogue Scale (VAS)</title>
          <description>The percentage of migraine attacks with the final (60 minute) VAS pain score either 0-1, or a 3-point improvement from baseline, was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
          <units>percentage of attacks</units>
          <param>Number</param>
          <units_analyzed>Migraine attacks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Migraine attacks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Visual Symptom Score 0-1 on the Visual Analog Scale (VAS)</title>
        <description>The percentage of migraine attacks with the final (60 minute) VAS visual symptom score 0-1 was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxygen</title>
            <description>Oxygen is inhaled for 30 minutes during migraine attack
Oxygen: Oxygen is inhaled for 30 minutes during migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Room Air</title>
            <description>Medical air inhaled for 30 minutes during migraine attack
Room air: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Final Visual Symptom Score 0-1 on the Visual Analog Scale (VAS)</title>
          <description>The percentage of migraine attacks with the final (60 minute) VAS visual symptom score 0-1 was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
          <units>percentage of attacks</units>
          <param>Number</param>
          <units_analyzed>Migraine attacks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Migraine attacks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Final Nausea Score 0-1 on the Visual Analog Scale (VAS)</title>
        <description>The percentage of migraine attacks with the final (60 minute) VAS nausea score 0-1 was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxygen</title>
            <description>Oxygen is inhaled for 30 minutes during migraine attack
Oxygen: Oxygen is inhaled for 30 minutes during migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Room Air</title>
            <description>Medical air inhaled for 30 minutes during migraine attack
Room air: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Final Nausea Score 0-1 on the Visual Analog Scale (VAS)</title>
          <description>The percentage of migraine attacks with the final (60 minute) VAS nausea score 0-1 was selected as a secondary outcome measure.
The VAS scale has a range from 0-10 with higher scores indicating greater severity of symptoms.</description>
          <units>percentage of attacks</units>
          <param>Number</param>
          <units_analyzed>Migraine attacks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Migraine attacks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Post-gas Therapy Medication Use</title>
        <description>The percentage of migraine attacks requiring the use of one or more anti-migraine medications after the period of gas inhalation, was selected as a secondary outcome measure.</description>
        <time_frame>60 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oxygen</title>
            <description>Oxygen is inhaled for 30 minutes during migraine attack
Oxygen: Oxygen is inhaled for 30 minutes during migraine attack</description>
          </group>
          <group group_id="O2">
            <title>Room Air</title>
            <description>Medical air inhaled for 30 minutes during migraine attack
Room air: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Post-gas Therapy Medication Use</title>
          <description>The percentage of migraine attacks requiring the use of one or more anti-migraine medications after the period of gas inhalation, was selected as a secondary outcome measure.</description>
          <units>percentage of attacks</units>
          <param>Number</param>
          <units_analyzed>Migraine attacks</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Migraine attacks</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time of enrollment and until a maximum of 4 migraine attacks were treated with gas inhalation and study equipment returned to the study team.</time_frame>
      <desc>Specific adverse events ('events of interest') were monitored around the time of each migraine attack (individual subjects had 1-4 migraine attacks each).</desc>
      <group_list>
        <group group_id="E1">
          <title>Oxygen</title>
          <description>Oxygen is inhaled for 30 minutes during migraine attack
Oxygen: Oxygen is inhaled for 30 minutes during migraine attack</description>
        </group>
        <group group_id="E2">
          <title>Room Air</title>
          <description>Medical air inhaled for 30 minutes during migraine attack
Room air: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tingling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Significant worsening of migraine headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aneesh Singhal, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6177268459 ext 4</phone>
      <email>asinghal@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

